Caliper Life Sciences and Seegene are teaming up to apply Seegene’s SeePlex™ multiplex diagnostic assays to Caliper’s LabChip® Dx platform. The firms say they will co-market the LabChip Dx platform and complete line of Seegene’s multiplex diagnostics straight away, and work together to expand the number of diagnostic tests available, which will be offered as co-branded products. Outside the U.S. the SeePlex assays will be marketed and distributed for use with the LabChip Dx through a preferred partnership agreement with Seegene’s distributors.
"Our unique SeePlex technology enables highly multiplexed PCR directly from clinical samples,” comments Jong-Yoon Chun, Seegene founder and CEO. “When coupled with Caliper’s microfluidics-based electrophoretic LabChip platforms, the SeePlex assays enable new paradigms for a variety of analytes in a fully automated and highly cost-effective manner.”
Seegene’s Dual Priming Oligonucleotide (DPO) approach to PCR-based assays uses a technique for DNA priming that is structurally and functionally different from traditional methods, the firm claims. “We believe that Seegene’s DPO technology uniquely enables sensitive and specific, highly multiplexed assays directly from clinical samples, significantly improving the economics of today for centralized and hospital-based diagnostic testing,” adds Kevin Hrusovsky, Caliper’s president and CEO. “This agreement to partner with Seegene’s innovative multiplex diagnostic content on the LabChip Dx platform should dramatically improve the economics of diagnostic testing and pave the way for the development of critical diagnostics to accelerate the worldwide implementation of personalized medicine.”